Immuno-Oncology Translation Network: Data Management and Resource-Sharing Center at RPCI

免疫肿瘤学翻译网络：RPCI 的数据管理和资源共享中心

• 批准号: 10558158
• 负责人: Alan David Hutson
• 金额: $ 10.55万
• 依托单位: ROSWELL PARK CANCER INSTITUTE CORP
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-07-01 至 2022-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10558158
• 关键词: Address; Atlas of Cancer Mortality in the United States; Bioconductor; Bioinformatics; Biostatistics Shared Resource; Cancer Center Support Grant; Clinical; Collaborations; Combined Modality Therapy; Communication; Communities; Data Management Resources; Dependence; Drug Kinetics; Drug resistance; Fostering; Immunooncology; Infrastructure; Malignant Neoplasms; Methods; Multiomic Data; Productivity; Research; Research Personnel; Resistance; Resource Sharing; Resources; Translations; anti-cancer therapeutic; biobank; cancer therapy; combat; data harmonization; data integration; data repository; design; drug sensitivity; expectation; experience; high standard; improved; innovation; metabolomics; multidisciplinary; outreach; predictive marker; real time monitoring; resistance mechanism; response; translational oncology; translational study; tumor

This application is being submitted in response to PA-20-272 Project Summary While several innovative and creative anti-cancer therapies have shown promising results, a significant expansion of their clinical use will require collaborative efforts to elucidate resistance mechanisms, exploit tumor sensitivity, map cancer dependence, discover new targets, identify predictive biomarkers, evaluate combination therapies, and develop real-time monitoring approaches. Leveraging cutting-edge multi- disciplinary team approaches, we will support the NCI Drug Resistance and Sensitivity Network (DRSN) to understand and combat mechanisms of tumor resistance and to exploit tumor sensitivity to anti-cancer therapies. Our strategy is to serve as an administration, communication, collaboration and analysis hub to coordinate the DRSN’s network-wide studies, focusing on reducing barriers to domain expertise, improving the productivity of DRSN investigators, maintaining a high standard for data harmonization and integration, designing and implementing rigorous analytical strategies, and fostering a collaborative and supportive research community. An experienced, multidisciplinary team has been assembled to pursue five Specific Aims: First, we will provide a centralized administration infrastructure to coordinate DRSN activities, building upon the Immuno- Oncology Translational Network (IOTN) Data Management and Resource-sharing Center (DMRC)’s well- functioning infrastructure that currently coordinates network studies under the umbrella of the NCI Cancer Moonshot initiative. Second, we will actively promote the DRSN and foster trans-consortium interactions, where we will leverage the IOTN DMRC’s demonstrable experience in Cross-Moonshot outreach and Bioconductor’s decades-long record in community-wide engagement. Third, we will provide multidisciplinary expertise to support DRSN collaborative research, leveraging four of the Roswell Park CCSG’s shared resources: Biostatistics, Bioinformatics, Data Bank and BioRepository, Bioanalytics, Metabolomics & Pharmacokinetics. Our analytic support will be armed with professional IT staff and informed by an experienced anti-cancer therapeutic researcher team. Fourth, we will develop innovative multi-omics data integration methods to enhance DRSN’s research capacity, capitalizing on the well-respected and highly- successful Bioconductor project. Fifth, we will disseminate resources developed in the DRSN to the broader community, unleashing the full potential of DRSN activities. Taken together, we envision our CC, in close collaboration with the DRSN components, will allow us to conduct highly effective and innovative translational studies to address the significantly unmet needs related to anti-cancer therapeutics, and fulfill the expectations and guiding principles of NCI Cancer Moonshot initiative.

该申请是根据PA-20-272提交的 项目摘要 虽然几种创新和创造性的反癌疗法已经显示出令人鼓舞的结果，但这是一个重要的 扩展其临床使用将需要协作努力来阐明抵抗机制，利用 肿瘤敏感性，地图癌症依赖性，发现新目标，识别预测性生物标志物，评估 组合疗法并开发实时监测方法。利用尖端的多 纪律团队的方法，我们将支持NCI耐药性和灵敏度网络（DRSN） 了解和战斗肿瘤耐药性的机制，并利用肿瘤对抗癌的敏感性 疗法。我们的策略是作为政府，沟通，协作和分析中心 协调DRSN的网络范围研究，重点是减少领域专业知识的障碍 DRSN研究人员的生产率，维持数据协调和集成的高标准， 设计和实施严格的分析策略，并培养协作和支持 研究社区。 一支经验丰富的多学科团队已经组装了五个具体目标：首先，我们将 提供集中的管理基础设施来协调DRSN活动，以免疫为基础 肿瘤转化网络（IOTN）数据管理和资源共享中心（DMRC）的良好 目前在NCI癌的伞下协调网络研究的基础设施的功能 Moonshot倡议。其次，我们将积极促进DRSN和促进跨性别的相互作用， 我们将利用Iotn DMRC在跨月型外展和 生物导体在社区范围内的数十年记录。第三，我们将提供多学科 支持DRSN合作研究的专业知识，利用Roswell Park CCSG共享的四个 资源：生物统计学，生物信息学，数据库和生物库，生物分析，代谢组学和 药代动力学。我们的分析支持将由专业的IT员工武装，并由 经验丰富的抗癌热研究人员团队。第四，我们将开发创新的多摩斯数据 综合方法来增强DRSN的研究能力，利用备受尊敬和高度尊敬的方法 成功的生物导体项目。第五，我们将传播DRSN中开发的资源，以更广泛 社区，释放DRSN活动的全部潜力。综上所述，我们在CC中设想 与DRSN组件的合作将使我们能够进行高效和创新的 转化研究以满足与抗癌治疗相关的明显未满足的需求，并满足 NCI Cancer Moonshot计划的期望和指导原则。